摘要
Primary sclerosing cholangitis （PSC） is a cholestatic disease characterized by chronic progressive bile duct inflammation and has a low incidence rate and poor prognosis in China. There is still no drug therapy that can change the course of PSC， and liver transplantation is the only effective treatment for PSC， with a 5-year survival rate of 85% after transplantation. Drug therapy for PSC is facing great challenges based on the current status of PSC. At present， drugs for the treatment of PSC are in the stage of clinical trials and have shown certain application prospect， among which ursodeoxycholic acid is the most widely studied and commonly used drug. In addition， there are many emerging drugs in the pipeline. This article summarizes the latest advances in drug therapy for PSC.
摘要
Objective: To explore the best method to treat post-stroke depression. Methods:60 Cases of the patients with post-stroke depression were selected and divided randomly into the two groups, 30 cases in each group. The treatment group was treated by scalp acupuncture plus body acupuncture, and the control group was treated by oral administration of Fluoxetine. The therapeutic effects were assessed after 30 d of the treatments. Results: The total effective rate was 90.0% in the treatment group, with average effective time of 5 d, and was 80.0% in the control group, with average effective time of 15 d. The comparison of the total effective rates between the two groups was not significant statistically (P＞0.05). But the comparison of the average effective time was significant statistically (P＜0.05). Conclusion: The therapeutic effect is positive in the treatment of post-stroke depression by scalp acupuncture plus body acupuncture, similar to the therapeutic effect of Fluoxetine, but faster in the effective time.